drugset / Trial / NCT03296787

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

NCT03296787

Phase 1 Completed 32 enrolled Takeda
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.

Timeline

Start
2017-11-21
Primary completion
2019-08-09
Completion
2019-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject felcisetrag Small molecule 0.2 mg Intravenous